Search Results 61-70 of 14451 for FMT and Ulcerative Colitis

  1. Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis · More about research at Mayo Clinic.

  2. A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis - Mayo Clinic

    The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis ( ...

  3. A Study to Evaluate both the Efficacy and Safety Profile of CP-690,550 in Patients with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or ...

  4. A Study of the Relationship Between Infliximab Levels and the Rate of Colectomies in Patients who have Ulcerative Colitis - Mayo Clinic

    The purpose of this study is to assess if infliximab drug levels in patients who have Ulcerative Colitis predict the risk of needing a colectomy. Additionally, ...

  5. Surgery remains an important treatment option for pediatric inflammatory bowel disease (IBD) - Mayo Clinic

    New medications have improved pediatric IBD care, but surgery is still an important option to cure ulcerative colitis and reduce Crohn's disease symptoms.

  6. Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis - Mayo Clinic

    ... ulcerative colitis (UC). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...

  7. Mayo Clinic Fecal Microbiota Transplant (FMT) Repository

    About this study. The aim of this protocol is to create a repository for frozen stool samples from donors of Mayo Clinic Rochester MN, FMT program.

  8. Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic

    The Food and Drug Administration approved the use of anti-tumor necrosis factor and anti-integrin agents for the treatment of ulcerative colitis in 2005 ...

  9. Study of GS-5290 in Participants With Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    Study of GS-5290 in Participants With Moderately-to-Severely Active Ulcerative Colitis · Overview · Participation eligibility · Participating Mayo Clinic locations.

  10. Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis - Mayo Clinic

    ... ulcerative colitis (UC). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...